Pepticom

Executive Summary

Pepticom is an Israeli biotech pioneering AI-driven generative design to discover novel therapeutic peptides. Its platform combines reinforcement learning, first-principles modeling, and structural data to explore a vast peptide space of ~10⁸⁰ candidates, generating peptides with enhanced stability, oral bioavailability, and target specificity. The company's lead program is an oral IL-17 inhibitor for plaque psoriasis, aiming to offer a convenient oral alternative to injected biologics. Pepticom plans to expand into other high-unmet-need indications. Founded in 2020 and currently preclinical, Pepticom has raised funding to advance its lead candidate toward the clinic.

Upcoming Catalysts (preview)

• Q3 2026Completion of IND-enabling studies for oral IL-17 inhibitor70% success
• Q1 2027IND filing with FDA60% success
• Q2 2027Initiation of Phase 1 clinical trial50% success